kstew call note manag upbeat outlook
call finish view manag commentari posit upbeat manag express confid
outlook net/net iew result call positiv believ stock react fav orabl
orn see upsid stock rate share equal weight
manag comment first quarter strong start year constant currenc sale result
better expect despit distributor destock quarter manag also note confid meet beat
guidanc year includ constant currenc sale growth expect case
focus urolift manag express pleas perform quarter outlook product
highlight sever present come american urolog associ aua meet kick tomorrow
question pleas reach us
here compani slide deck call link
 head time year againinstitut investor survey vote season want express ii import
import barclay would appreci support vote medic suppli devic categori dont feel
ive earn vote pleas let know futur thank support
revenu grew report basi constant currenc basi initi expect
manag pleas ith broad-bas grow th product geograph perspect grow th led
grow th intervent urolog grow th intervent access grow th oem geograph strong
grow th ithin asia america perform exampl divers acceler revenu grow th
gross margin oper margin ep latter repres y/i adjust ep slightli
better expect despit greater fx headw ind y/i increas tariff
result give increas confid achiev guidanc reaffirm guidanc rang report constant currenc adjust
gross oper margin ep
perform region
america constant currenc basi driven intervent urolog intervent access product famili
emea constant currenc basi lead intervent access vascular product
asia constant currenc basi driven vascular intervent access surgic product china
also saw korea se asia strength
oem constant currenc basi lead cathet perform fiber pleas ith grow th rate expect
grow upper singl digit full year
sale product categori
vascular access sale ere constant currenc basi strong picc cvc sale off-set time
intervent access sale increas constant currenc basi strength broad base ith grow th legaci
intra-aort balloon iab consum on-control bone marrow part vsi solut manta enter limit
market releas strategi continu method roll achiev outcom continu expect revenu
contribut immateri grow th
anesthesia sale dow constant currenc basi primarili due time distributor order laryng mask
repla focus complet bla submiss
surgic driven ligat clip surgic instrument pleas see rebound surgic grow th rate
longer face product line exit
intervent urolog urolift sale grew constant currenc basi sale forc continu make good
progress drive adopt end field sale forc rep associ continu build team
market penetr team urologist unit state continu make progress train
us physician base median lobe indic ill begin urolift roll-out train median lobe hich ill
latter half expect full convers us physician base ork bring urolift japan move
reimburs process expect mid late releas ith meaning releas reaffirm
intervent urolog grow th goal approxim
sale hich includ respiratori urolog care product cc basi attribut respiratori
bladder manag due distributor purchas dynam impact vascular anesthesia
highlight upcom american urolog associ meet
symptom sexual function outcom find suggest patient improv ith preserv function
continu invest industri lead bodi evid
pleas ith broad base result invest higher margin busi
gross profit adjust basi increas prior year adjust gross margin
expans reflect increas urolift sale volum cost benefit restructur neg fx tariff inflat
oper margin dow neg impact fx increment tariff inflat neg impact gross
margin also impact oper margin plan increas commerci invest urolift currenc neutral basi
oper margin
interest expens dow y/i due cross currenc sw ap
tax rate vs prior year increas due mix earn tax jurisdict y/i ell reduc sbc benefit
ep increas y/i includ fx headw ind y/i tarfif divestitur reprocess prior year
cfo vs year ago decreas due conting consider payment
debt unchang
 eek quarter enter revolv credit facil term loan coven leverag net
leverag previous gross leverag end march net leverag
reaffirm sale grow th expect constant currenc grow th report grow th
reaffirm adjust gross oper margin rang
reduc guidanc oper margin due conting consider impair certain intang
full year interest expens expect still ever expect closer low end rang due
fed maintain rate versu rate increas expect previous includ benefit interest rate sw ap march
reduc ep rang
rang contempl higher invest higher grow th margin categori
pleas grow ep hile fund invest offset headw ind fx tarrif
excel begin pleas ith expect result believ strong set nice achiev previous
question answer question answ er manag respons verbatim
intervent strong perform sustain intervent perform ell quarter broad base grow th
 legaci perform ell quarter iab pump cathet microcathet product vsi busi still
expect full year basi high singl mayb make doubl digit quit bullish intervent access one area
highlight ould grow th driver year
comp get harder pipelin improv think overal happi ith start
sure focu comp last year toughest comp busi solid headw ind tailw ind
year cathet reprocess busi exit oem expect grow year like
high singl digit tailw ind destock distributor vascular anesthesia categori
intervent access busi expect grow high singl digit mayb sneak doubl digit apac high singl
digit surgic happi see recoveri mid-singl digit rang full year neotract start realli
realli strong full year number think good set full year
neotract start realli strong grow th guidanc full year number encourag start
urolift could get reimburs japan faster reimburs mid late start roll-out
lrp littl revenu japan
urolift roll-out urolift time ill convers complet
free gener year cfo impact increas conting consider reduc cfo look full year
expect full year plan
distributor roll busi organ less distributor use half busi one-
third saw de-stock anticip expect come back over-cam quarter deliv better
see distributor destock differ dynam ith distributor much hold
custom organ one ould think
guidanc given strong start year talk philosoph guidanc feel realli great
busi think continu throughout remaind year think strong posit meet exceed guidanc go
year ill take look sharpen dow pencil urolift think great start approxim
grow th full year number great start eaker comp voluntari recal promis start year
intervent access growth piec highlight intervent broad base on-control grew nearli
cathet extens micro cathet biolog ell number iab solid start doubl digit around
neotract growth out-performance anyth differ trend perspect metric look train urologist
train unit state revenu come continu see come outsid
hospit offic momentum build area chang site servic revenu come
excit train urologist store sale increas quarter quarter ouldnt expect chang rep
product ith urolift product per rep around annual continu invest dtc doubl number
year continu add sale rep everi year
vascular access picc almost continu take share believ behind bard/bd cvc busi nice quarter even
 ith destock grow th equal drive area ith better margin
 capac someth updat think talk funnel leverag ratio net
abil capac
urolift reimburs think reimburs competitor procedur offic base procedur dont
think impact grow th focus go deep dont see competitor impact grow th
manta contribut year look outward excit manta commenc us limit
market releas test price make sure train right level product sticki tavr center
less center us clinic data compel ith reduct major complic dont expect
signific revenu roll-out limit ay
write intang size relat qt vascular includ paclitaxel coat product option
 includ transact given paclitaxel concern market place rite
urolift ant methodolog dont ant impact grow th ith train keep grow th acceler hile
convert physician also go back urologist smaller number case month retrain
urolift japan direct distributor intent build sale forc throughout japan ill put feet street
japan reimburs ould envis dont know hat ill get feel japanes author align
 ith us expect close reimburs us ould happi ith result
tariff impact go away look tariff estim full year basi go aw ay potenti
benefit quarter
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog set price target primarili reli forw ard price-to-earnings methodolog price target
appli pe multipl ep estim
risk may imped achiev barclay research valuat price upsid extent neotract
urolift sale higher expect could drive upsid sale earn lead higher pe nside urolift sale
disappoint core grow th fail improv fx stronger us dollar higher interest rate half debt float
risk includ time receipt new product approv competit pressur particularli key product like urolift
signific chang reimburs fda govern action
rate price target histori
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
price sourc refinitiv last avail close price relev trade market unless anoth time sourc
indic
